Literature DB >> 32042890

Platinum (II) complex-nuclear localization sequence peptide hybrid for overcoming platinum resistance in cancer therapy.

Marek T Wlodarczyk1,2, Sylwia A Dragulska1, Olga Camacho-Vanegas3, Peter R Dottino4, Andrzej A Jarzęcki1, John A Martignetti3,5, Aneta J Mieszawska1.   

Abstract

Platinum therapy represents first line of treatment in many malignancies but its high systemic toxicity limits the therapeutic dosage. Herein, we report the synthesis of carboplatin-like complexes with azide and alkyne functional groups and the formation of a platinum (II) - nuclear localization sequence peptide (Pt-NLS) hybrid to improve the import of platinum (II) complexes directly into the cell's nucleus. The Pt-NLS hybrid successfully enters cells and their nuclei, forming Pt-induced nuclear lesions. The in vitro efficacy of Pt-NLS is high, superior to native carboplatin at the same concentration. The methodology used is simple and cost-effective and most importantly can easily be extended to load the Pt (II) onto other supports, opening new possibilities for enhanced delivery of Pt (II) therapy.

Entities:  

Keywords:  NLS peptides; chemoresistant; click chemistry; platinum (II) complexes

Year:  2018        PMID: 32042890      PMCID: PMC7009786          DOI: 10.1021/acsbiomaterials.7b00921

Source DB:  PubMed          Journal:  ACS Biomater Sci Eng        ISSN: 2373-9878


  32 in total

1.  Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides.

Authors:  Anna Massaguer; Alejandro González-Cantó; Esther Escribano; Silvia Barrabés; Gerard Artigas; Virtudes Moreno; Vicente Marchán
Journal:  Dalton Trans       Date:  2015-01-07       Impact factor: 4.390

2.  Alkaline hydrolysis of oxaliplatin--isolation and identification of the oxalato monodentate intermediate.

Authors:  Elin Jerremalm; Pernilla Videhult; Gunvor Alvelius; William J Griffiths; Tomas Bergman; Staffan Eksborg; Hans Ehrsson
Journal:  J Pharm Sci       Date:  2002-10       Impact factor: 3.534

3.  Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation.

Authors:  R J Parker; A Eastman; F Bostick-Bruton; E Reed
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

4.  Unprecedented sugar-dependent in vivo antitumor activity of carbohydrate-pendant cis-diamminedichloroplatinum(II) complexes.

Authors:  Y Mikata; Y Shinohara; K Yoneda; Y Nakamura; I Brudziñska; T Tanase; T Kitayama; R Takagi; T Okamoto; I Kinoshita; M Doe; C Orvig; S Yano
Journal:  Bioorg Med Chem Lett       Date:  2001-12-03       Impact factor: 2.823

5.  Stability of carboplatin and oxaliplatin in their infusion solutions is due to self-association.

Authors:  Anthony J Di Pasqua; Deborah J Kerwood; Yi Shi; Jerry Goodisman; James C Dabrowiak
Journal:  Dalton Trans       Date:  2011-04-04       Impact factor: 4.390

6.  Synthesis of 17beta-estradiol platinum(II) complexes: biological evaluation on breast cancer cell lines.

Authors:  Caroline Descôteaux; Josée Provencher-Mandeville; Isabelle Mathieu; Valérie Perron; Sanat K Mandal; Eric Asselin; Gervais Bérubé
Journal:  Bioorg Med Chem Lett       Date:  2003-11-17       Impact factor: 2.823

7.  cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II).

Authors:  A M Fichtinger-Schepman; A T van Oosterom; P H Lohman; F Berends
Journal:  Cancer Res       Date:  1987-06-01       Impact factor: 12.701

8.  Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model.

Authors:  Amr Abu-Lila; Takuya Suzuki; Yusuke Doi; Tatsuhiro Ishida; Hiroshi Kiwada
Journal:  J Control Release       Date:  2008-11-05       Impact factor: 9.776

9.  Targeting mitochondrial DNA with a platinum-based anticancer agent.

Authors:  Simon P Wisnovsky; Justin J Wilson; Robert J Radford; Mark P Pereira; Maria R Chan; Rebecca R Laposa; Stephen J Lippard; Shana O Kelley
Journal:  Chem Biol       Date:  2013-10-31

10.  Evaluating cell lines as tumour models by comparison of genomic profiles.

Authors:  Silvia Domcke; Rileen Sinha; Douglas A Levine; Chris Sander; Nikolaus Schultz
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

View more
  6 in total

1.  Engineering of hybrid anticancer drug-loaded polymeric nanoparticles delivery system for the treatment and care of lung cancer therapy.

Authors:  Yang Zhao; Kefeng Liu; Jie Li; Juan Liao; Li Ma
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.819

Review 2.  Platinum-based drugs for cancer therapy and anti-tumor strategies.

Authors:  Chunyu Zhang; Chao Xu; Xueyun Gao; Qingqiang Yao
Journal:  Theranostics       Date:  2022-02-07       Impact factor: 11.556

Review 3.  Investigating the role of peptides in effective therapies against cancer.

Authors:  Reza Naeimi; Asrin Bahmani; Saeid Afshar
Journal:  Cancer Cell Int       Date:  2022-03-27       Impact factor: 5.722

4.  A click-based modular approach to introduction of peroxides onto molecules and nanostructures.

Authors:  Alissa Horn; Patrick H Dussault
Journal:  RSC Adv       Date:  2020-12-16       Impact factor: 4.036

Review 5.  Recent advances in metallopolymer-based drug delivery systems.

Authors:  Gulzhian I Dzhardimalieva; Lev N Rabinskiy; Kamila A Kydralieva; Igor E Uflyand
Journal:  RSC Adv       Date:  2019-11-13       Impact factor: 4.036

6.  Co-drug delivery of regorafenib and cisplatin with amphiphilic copolymer nanoparticles: enhanced in vivo antitumor cancer therapy in nursing care.

Authors:  Zhe Zhou
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.